Member Info for daveycaferacer

I agree Jatw, particularly with regards to U.S. investors and the reasons they invest in smaller Biotech's eg. Juno, Tesaro etc etc, they just want the upside when they are acquired by big Pharma, often 50%+

Interesting observation about Orange and Vodafone.....

"Its a good time to buy if you want to double your money before end of year .."

Similar things have been said many many times in the last few years I'm afraid

Not sure amones, all I follow and have seen is some coverage in the scmp but whether there is any coverage in mainland China I 'm not sure. That said I don't think Chinese Investors other than Banks can invest in shares listed outside China. All I know is the following headwinds are not helping at the moment!:-

Current Headwinds
1. HHHL/CKH secondary listing overhang
2. U.S. - China trade war
3. Hong Kong stability
4. Delay to HK IPO
5. Worldwide markets volatility
6. Trump China ADR de-listing threat (which has now been confirmed to be false)
7. China disliked by the U.S. and its Investment Community

I am still buying

I was expecting a £1m placing at 0.4 pence so £1.5m at 0.45 pence is better than I expected. I cannot see us maintaining the current price for a while.

The volumes on NASDAQ have almost dried up completely in the last week, it appears Investors are no longer willing to invest, although that may well be a wider market symptom as people seek safe havens and Gold continues its upward trajectory.

I continue to buy

Within a few months of the last placing the share price dropped by 50%, I hope we do not experience the same again. Currently as everyone knows a placing is imminent any potential Buyers will hold off until after the placing, with the though the same drop will re-occur.

£320,279 at 30th June, so with the current burn rate we will run out of money by the end of the year at the very latest

It is Interesting that the spread has now tightened since the CKHH disposal and hopefully closure of the overhang

It seems to me the biggest detractor to the valuation at the moment is the CKHH overhang, which has probably put off Institutional Investors. Now that is cleared hopefully we can get back to something more sensible. The market liked that piece of news yesterday and volumes on NASDAQ were higher than they have been for some time too.

I think TD are correct, the true theoretical value (not Broker target) is £5.93 per share based on the IP, DCF etc

Trinity Delta have issued an updated note today

https://www.trinitydelta.org/research-notes/esmo-2019-surufatinib-epnet-pfs-benefit-confirmed/

thx Amones, I am at a loss as to why the market is valuing the Company at current levels. I assume this is due to a mix of the following:-

1. HHHL/CKH secondary listing overhang
2. U.S. - China trade war
3. Hong Kong riots
4. Delay to HK IPO
5. Worldwide markets volatility
6. Trump China ADR de-listing threat (proven to be a false report)
7. U.S. Investor sentiment towards China and Chinese stocks given the trade war and China's reputation for IP theft

It seems to me that the market is not valuing the Company based on its pipeline, financial performance or proper metrics such as DCF calculations and value of its IP.

I continue to remain substantially invested because I believe in the Company, its strategy & vision, proven execution and brilliant Management Team, but this is a frustrating time for Investors. They are also delivering substantial benefits to patients of course. I continue to Buy.

https://www.fiercepharma.com/pharma-asia/esmo-eyeing-novartis-and-pfizer-chi-med-touts-neuroendocrine-cancer-phase-3-win

I did think that Cariie Lam's pulling of the extradition bill would bring the riots to an end, but it seems the Protestors will continue this cause. In the meantime a number of Biotech's have continued with their HK listings.

Ad for Trump let's hope there is major progress at the next trade talks on the 10th October.

https://www.cnbc.com/2019/09/30/peter-navarro-reports-that-us-would-restrict-chinese-companies-were-fake-news.html

$17.65 compares terribly to the last tranche @ $24............ CKHH cannot be too happy with that

I continue to buy

The offering price was US$17.65 per American depositary share ("ADS").

We knew this was coming of course, but its impact is far larger than I expected

30 months of growth wiped out

Another Secondary Offering on top of Trumps diatribe about de-listing China ADR's, the bad news keeps on coming, all outside the control of this brilliant Company, unfortunately

I bought another tyranches early this morning but wish I had waited until this news hit the market

CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term
London: Monday, September 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that its shareholder CK Hutchison Holdings Limited (“CK Hutchison”) (SEHK: 1)[1] is launching an offering to sell approximately 1.3% of the total outstanding share capital in Chi-Med’s through an underwritten public offering, which would reduce its stake in Chi-Med from 51.1% to 49.9% (the “Offering”).
CK Hutchison has announced that, upon completion of the Offering, it has no intention of selling additional Chi-Med shares for the foreseeable future.
Canning Fok, Group Co-Managing Director of CK Hutchison, commented: “Upon completion of the Offering, we will have achieved our previously announced objective of reducing our shareholding in Chi-Med to below 50%, and this will enable CK Hutchison to deconsolidate Chi-Med in the financial statements of CK Hutchison.”
CK Hutchison plans to maintain its shareholding in Chi-Med as a strategic investment for the long term as it continues to strive to become a global biopharmaceutical company.
The CK Hutchison announcement is attached.